Menu ×


Dexrazoxane Market Segmentation By Product Type (250mg and 500mg) and By End User (Hospitals and Drugstore) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Dexrazoxane Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • April 2018: Hikma Pharmaceuticals PLC announced that it has launched dexrazoxane for injections which is the generic equivalent to Zinecard®. The introduced vials are available in sizes of 250mg and 500mg.
  • September 2017: Cumberland Pharmaceuticals Inc. announced that it has started the promotion in the United States for its dexrazoxane hydrochloride injection, known as Totect®.

Introduction To Dexrazoxane

Dexrazoxane hydrochloride is a cardioprotective drug. Dexrazoxane is used to protect the heart from cardiotoxic adverse effects of chemotherapeutic drugs, such as anthracyclines, daunorubicin, doxorubicin, etc. For the prevention of cardiomyopathy for adults and children aged 0 to 16 years, dexrazoxane was approved by the US FDA as an orphan drug for treatment with an anthracycline. Almost all children are required to receive dexrazoxane at the discretion of the care physician starting with the first dose of anthracycline.

Market Size and Forecast

With the rising cases of cancer around the globe, there is a significant increase in medical advances in the healthcare industry owing to the fact that it has the potential to improve healthcare and is considered to be the necessary solution for the clinical practice. Thus, there is a shift in towards using dexrazoxane in healthcare which will enhance the market growth. The dexrazoxane market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by product, and by end-user. In the product type, it is segmented into 250mg and 500mg. By the end-user type, it is segmented into hospitals and drugstores. Among these, the hospital segment is likely to have the largest CAGR over the forecast period owing to the fact that many cancer operating hospitals have their own pharmacies or medicine outlets and hence they deliver the drug straight without going to the drugstore.

Growth Drivers

Upsurge In The Number Of Cancer Patients Around The Globe

According to the International Agency for Research on Cancer (IARC), a Global Observatory on Cancer that provides an estimate of the incidence and mortality of 36 kinds of cancer in 185 countries and all cancer sites integrated,  stated that according to estimates, the global cancer burden increased to 18.1 million new cases and 9.6 million deaths reported in 2018. Over their lifespan, one in five men and one in six women across the world grow cancer, and one in eight men and one in eleven women die from heart disease. The cumulative number of people living within 5 years of a diagnosis of cancer, called the 5-year preponderance, is approximated at 43.8 million worldwide

As there is a rise in the number of cancer patients around the globe, the usage of anthracycline has increased thus dexrazoxane an antimitotic, immunosuppressive agent is used to reduce the toxicity. Dexrazoxane, is the razoxane enantiomorph, provides for the cardioprotection against toxicity to anthracycline. The Food and Drug Administration has approved dexrazoxane as an approved medication to be used in the prevention and reduction of the incidence and severity of cardiomyopathy caused by anthracycline all these factors are the growth drivers and this is anticipated to significantly expand the dexrazoxane market. CLICK TO DOWNLOAD SAMPLE REPORT


High Dosage, Leading to Side Effects

Despite the growing market for the dexrazoxane, the drug might have some side effects after heavy dosage or being used by the pediatric patients which may lead to leukopenia, granulocytopenia, and thrombocytopenia and is likely to hamper the growth of the market.

Market Segmentation

Our in-depth analysis of the global dexrazoxane market includes the following segments:

By Product Type

  • 250mg
  • 500mg

By End User

  • Hospitals
  • Drugstore

By Region

Based on regional analysis, the dexrazoxane market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America, followed by Europe, holds a significant share of the world dexrazoxane market, owing to the native presence of more advanced institutions for cancer treatments, successful implementation of dexrazoxane in the medical field, improved healthcare facilities. Latin America is predicted to exhibit vital growth within the dexrazoxane market over the forecast period. Additionally, government initiatives to improve healthcare by the formation of enticing policies in countries like China and India are predicted to spice up the dexrazoxane business, which is predicted to considerably contribute towards the expansion of the dexrazoxane market throughout the forecast period.

The dexrazoxane market is further classified based on region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved